In last trading session, RedHill Biopharma Ltd. (NASDAQ:RDHL) saw 1.62 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $2.40 trading at -$0.04 or -1.64% at ring of the bell on the day assigns it a market valuation of $120.84M. That closing price of RDHL’s stock is at a discount of -380.0% from its 52-week high price of $11.52 and is indicating a premium of 6.67% from its 52-week low price of $2.24. Taking a look at company’s average trading volume of 812.03K if we extend that period to 3-months.
For RedHill Biopharma Ltd. (RDHL), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.70. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.26 in the current quarter.
RedHill Biopharma Ltd. (NASDAQ:RDHL) trade information
Upright in the red during last session for losing -1.64%, in the last five days RDHL remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $2.40 price level, adding 9.43% to its value on the day. RedHill Biopharma Ltd.’s shares saw a change of -6.98% in year-to-date performance and have moved -2.04% in past 5-day. RedHill Biopharma Ltd. (NASDAQ:RDHL) showed a performance of -10.78% in past 30-days.
Wall Street analysts have assigned a consensus price target of $14.14 to the stock, which implies a rise of 83.03% to its current value. Analysts have been projecting $7.00 as a low price target for the stock while placing it at a high target of $22.00. It follows that stock’s current price would drop -816.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -191.67% for stock’s current value.
RedHill Biopharma Ltd. (RDHL) estimates and forecasts
Statistics highlight that RedHill Biopharma Ltd. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -59.80% of value to its shares in past 6 months, showing an annual growth rate of 23.81% while that of industry is 16.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 62.90% in the current quarter and calculating 28.00% increase in the next quarter. This year revenue growth is estimated to rise 37.50% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $24.52 million for the same. And 1 analysts are in estimates of company making revenue of $25 million in the next quarter that will end on Mar 2022. Company posted $21.46 million and $20.57 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 14.30% while estimating it to be 21.50% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.90% during past 5 years.
RedHill Biopharma Ltd. is more likely to be releasing its next quarterly report between March 16 and March 21 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
RedHill Biopharma Ltd. (NASDAQ:RDHL)’s Major holders
Insiders are in possession of 0.03% of company’s total shares while institution are holding 13.49 percent of that, with stock having share float percentage of 13.49%. Investors also watch the number of corporate investors in a company very closely, which is 13.49% institutions for RedHill Biopharma Ltd. that are currently holding shares of the company. Disciplined Growth Investors, Inc. is the top institutional holder at RDHL for having 1.98 million shares of worth $9.05 million. And as of Sep 29, 2021, it was holding 3.77% of the company’s outstanding shares.
The second largest institutional holder is Ibex Investors LLC, which was holding about 0.72 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 1.37% of outstanding shares, having a total worth of $3.28 million.
On the other hand, iShares NASDAQ Biotechnology ETF and ETF Managers Tr-BlueStar TA-BIGI Tech Israel Technology ETF are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 0.26 million shares of worth $1.42 million or 0.50% of the total outstanding shares. The later fund manager was in possession of 55930.0 shares on Sep 29, 2021, making its stake of worth around $0.26 million in the company or a holder of 0.11% of company’s stock.